Khalil Fenina's questions to PTC Therapeutics Inc (PTCT) leadership • Q4 2024
Question
Khalil Fenina, on behalf of Paul Choi, asked about the company's capital deployment plans for the remainder of the year, given its strong cash position and proximity to operational breakeven.
Answer
CEO Dr. Matthew Klein reiterated that the company's strong cash position was built without assuming European Translarna revenue, making any ongoing sales upside. He stated the capital is sufficient to reach cash flow breakeven without needing to raise additional funds and also allows for strategic business development to augment the portfolio.